- ASSISTANT PROFESSOR Medicine, Nephrology
American Board of Internal Medicine
Dr. Harbord is a Specialist in Clinical Hypertension (ASH), with an interest in diabetic kidney disease, critical care nephrology and acute kidney injury, chronic kidney disease, edematous states, and electrolyte and acid-base disorders.
Dr. Nikolas Harbord received his medical degree from the UMDNJ-Robert Wood Johnson Medical School (now Rutgers Medical School), and completed both his internal medicine residency and nephrology fellowship at Beth Israel Medical Center (now Mount Sinai Beth Israel). Dr. Harbord is board certified in internal medicine and nephrology. He has served as the program director for the nephrology fellowship since 2012, and as interim division chief since 2014.
Dr. Harbord administers the division of nephrology and the nephrology fellowship program. He directs the weekly diabetic nephropathy clinic at the Friedman Diabetes Center. Dr. Harbord serves MSBI on the pharmacy and therapeutics committee and the Mount Sinai Health System on the Department of Medicine clinical trials review committee. He has published on various topics within nephrology, including nephrotoxicity and mineral bone disease. He was named a New York Rising Star in Nephrology in 2013 & 2014 by Superdoctors.com & NY Times Magazine. He maintains an active dialysis and office practice, and accepts new patients.
2013, 2014 -
New York Rising Stars- Nephrology
Superdoctors.com & NY Times Magazine
I have helped to describe the association between bisphosphonate therapy and adynamic bone disease in CKD patients, by using dynamic bone labeling and bone histology. With my colleagues at MSBI, I have described the inflammation evident in ESRD patients with various types of hemodialysis access. As a co-investigator in an industry funded clinical trial [Multi-Center Study of the Effect of Sevelamer Carbonate on Metabolic/Inflammatory/Reactive Oxygen Species (ROS) in Diabetes with Nephropathy, the AGELESS study] at MSBI and Mount Sinai, I helped recruit study subjects and am involved in the current publication of our findings. I have also guided the comprehensive survey of the impact of Hurricane Sandy on hemodialysis patients in NYC; and will soon publish our findings. As the training program director and division chief (interim) for Nephrology & Hypertension at MSBI I will be responsible for promoting scholarly activity and research among all fellows and faculty.
Harbord N. Novel nephrotoxins. Advances in chronic kidney disease 2011 May; 18(3).
Harbord N, Amerling R. Fluid and electrolyte balance in tennis players. Nephrology news & issues 2011 Apr; 25(4).
Winchester JF, Harbord NB, Rosen H. Management of poisonings: core curriculum 2010. American journal of kidney diseases : the official journal of the National Kidney Foundation 2010 Oct; 56(4).
Amerling R, Harbord NB, Pullman J, Feinfeld DA. Bisphosphonate use in chronic kidney disease: association with adynamic bone disease in a bone histology series. Blood purification 2010; 29(3).
Winchester JF, Harbord N, Charen E, Ghannoum M. Use of Dialysis and Hemoperfusion in the Treatment of Poisoning . In: Daugirdas J, Blake P, Ing T, editors. Handbook of Dialysis (5th Edition).
Feinfeld DA, Harbord N. Renal Principles. In: Goldfrank , Flomenbaum , Lewin , editors. Goldfrank's Toxicologic Emergencies (9th Edition). New York, McGraw Hill Medical;.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr. Harbord did not report having any of the following types of financial relationships with industry during 2014 and/or 2015: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website at http://icahn.mssm.edu/about-us/services-and-resources/faculty-resources/handbooks-and-policies/faculty-handbook. Patients may wish to ask their physician about the activities they perform for companies.